Direct-to-Patient Drug Programs Changing the Pharmacy Ecosystem

The rapid rise of GLP-1 medications has done more than transform treatment options. It’s exposed longstanding challenges in how Americans access and pay for prescription drugs and accelerated the search for better ways to connect patients with medications.

For Rae McMahan, SVP of Payer Solutions at Prescryptive, these developments represent an important shift in the pharmacy benefits landscape.

In a recent episode of the Empowered Patient Podcast with host Karen Jagoda, McMahan explores how direct-to-patient and manufacturer-sponsored drug programs are challenging traditional approaches to prescription access.

McMahan brings an important perspective to this conversation: understanding how changes in the pharmaceutical market translate into real decisions for employers and the people who depend on their benefits.

As manufacturers explore new ways to reach patients, employers have an opportunity to rethink how they deliver pharmacy benefits. The challenge is no longer simply managing prescription drug costs. It’s creating access that combines affordability, medication choice, and a simpler patient experience.

And while GLP-1 medications have accelerated the conversation, the implications extend well beyond one drug category. The emergence of direct models raises a larger question for the industry: How can new pathways to prescription drugs work together with employer benefits, pharmacies, and existing healthcare systems?

At Prescryptive, we believe the answer lies in connecting these pathways through neutral infrastructure that puts patient access first.

Listen to Rae’s conversation on the Empowered Patient Podcast to hear her perspective on the changing pharmacy ecosystem and what it means for the future of prescription drug access.